1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsInvestigator Sponsored Studies (ISS) Program is sponsored by Vertex Pharmaceuticals. Funds independent, investigator-initiated research advancing scientific understanding and patient care in sickle cell disease.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Investigator Sponsored Studies by Vertex Pharmaceuticals | Atom Grants Investigator Sponsored Studies Vertex Pharmaceuticals funds independent research to advance scientific knowledge and treatment in cystic fibrosis, sickle cell disease, beta thalassemia, IgA nephropathy, and pain.
Funder: Vertex Pharmaceuticals Due Dates: Rolling (CF, IgA nephropathy, Pain) | RFP-based (Beta thalassemia & Sickle cell disease; currently closed) Funding Amounts: No strict cap; budgets must reflect fair market value and generally not exceed 35% overhead. Multi-year funding possible.
Summary: Funds independent investigator-initiated research advancing knowledge in cystic fibrosis, sickle cell disease, beta thalassemia, IgA nephropathy, and pain. Key Information: Pain proposals accepted only from U.S.; beta thalassemia and sickle cell disease applications only during RFP cycles.
Vertex Pharmaceuticals’ Investigator Sponsored Studies (ISS) program supports independent, investigator-initiated research that advances scientific understanding of disease states, patient populations, and medical treatments aligned with Vertex’s clinical and scientific priorities.
The program funds clinical, observational, and nonclinical studies, including those involving Vertex compounds, in key disease areas such as cystic fibrosis, sickle cell disease, beta thalassemia, IgA nephropathy, and pain. The ISS program is intended to foster scientific innovation and collaboration with external researchers to improve patient outcomes in serious diseases. See the full grant listing
According to the current listing, eligibility includes: Academic institutions, research organizations, and healthcare professionals conducting research in sickle cell disease. Confirm the full requirements in the official notice before applying.
Investigator Sponsored Studies (ISS) Program is funded by Vertex Pharmaceuticals. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.